{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Kent DM"],"funding":["NCATS NIH HHS"],"pagination":["2277-2286"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8672231"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["326(22)"],"pubmed_abstract":["<h4>Importance</h4>Patent foramen ovale (PFO)-associated strokes comprise approximately 10% of ischemic strokes in adults aged 18 to 60 years. While device closure decreases stroke recurrence risk overall, the best treatment for any individual is often unclear.<h4>Objective</h4>To evaluate heterogeneity of treatment effect of PFO closure on stroke recurrence based on previously developed scoring systems.<h4>Design, setting, and participants</h4>Investigators for the Systematic, Collaborative, PFO Closure Evaluation (SCOPE) Consortium pooled individual patient data from all 6 randomized clinical trials that compared PFO closure plus medical therapy vs medical therapy alone in patients with PFO-associated stroke, and included a total of 3740 participants. The trials were conducted worldwide "],"journal":["JAMA"],"pubmed_title":["Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke."],"pmcid":["PMC8672231"],"funding_grant_id":["UL1 TR002544"],"pubmed_authors":["Song JK","Nelson J","Lee PH","Soendergaard L","Derumeaux G","Chatellier G","Furlan AJ","Lefebvre B","Carroll JD","Smalling RW","Koethe B","Kim JS","Thaler DE","Saver JL","Meier B","Reisman M","Herrmann HC","Mas JL","Kasner SE","Mattle HP","Kent DM","Juni P"],"additional_accession":[]},"is_claimable":false,"name":"Heterogeneity of Treatment Effects in an Analysis of Pooled Individual Patient Data From Randomized Trials of Device Closure of Patent Foramen Ovale After Stroke.","description":"<h4>Importance</h4>Patent foramen ovale (PFO)-associated strokes comprise approximately 10% of ischemic strokes in adults aged 18 to 60 years. While device closure decreases stroke recurrence risk overall, the best treatment for any individual is often unclear.<h4>Objective</h4>To evaluate heterogeneity of treatment effect of PFO closure on stroke recurrence based on previously developed scoring systems.<h4>Design, setting, and participants</h4>Investigators for the Systematic, Collaborative, PFO Closure Evaluation (SCOPE) Consortium pooled individual patient data from all 6 randomized clinical trials that compared PFO closure plus medical therapy vs medical therapy alone in patients with PFO-associated stroke, and included a total of 3740 participants. The trials were conducted worldwide ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Dec","modification":"2025-05-18T12:49:54.323Z","creation":"2025-04-06T09:05:10.218Z"},"accession":"S-EPMC8672231","cross_references":{"pubmed":["34905030"],"doi":["10.1001/jama.2021.20956"]}}